Bayer AG NA
5-year stock timeline
Bayer AG (BAYN.XETRA) has moved through distinct phases over the past five years, each marked by specific turning points.
The settlement era and portfolio reset
In June 2020, Bayer announced agreements to resolve most legacy Monsanto and Roundup litigation, with total payments in the $10.1–$10.9 billion range. That anchor point freed the company to pursue a deliberate portfolio strategy: the Animal Health sale closed in 2020, Environmental Science Professional followed in 2022, and targeted pharma acquisitions like Vividion began rebuilding the pipeline. The moves were methodical, each one reducing a specific drag on the narrative.
Narrative shift from trap to normalization
The market initially treated Bayer as a litigation-laden value trap, fixated on residual legal risk and execution questions. By 2022–2024 that lens had shifted. Divestments and cost discipline reduced headline risk and lifted reported metrics. The story stopped being about what could go wrong and started being about what was actually improving.
Structural clarity and re-rating catalysts
Bill Anderson's arrival as CEO in early 2023 accelerated the pace. A formal strategic review that explicitly considered separating Crop Science gave investors something concrete to model. Then in May 2026, the acquisition of Perfuse Therapeutics (up to $2.45 billion) signaled a deliberate move into ophthalmology—not a defensive hold, but a targeted growth bet. The stock has moved with clearer conviction since then, and the Perfuse deal provided the kind of tangible catalyst that can sustain momentum beyond sentiment alone.
The current price of 38.12 reflects a company no longer defined by what it's trying to escape, but by where it's choosing to go.
Key risks and downside factors
Bayer operates three distinct businesses—Pharmaceuticals, Crop Science and Consumer Health—each competing against large, specialized rivals. Roche and Novartis dominate pharmaceuticals; Corteva and BASF lead in crop science [3][2]. The company carries a complex risk profile: legacy litigation and regulatory exposure inherited from its Monsanto acquisition, combined with persistent pricing pressure and generic competition in crop protection, plus the relentless R&D and payer dynamics that characterize pharmaceuticals [3][9].
- The Monsanto acquisition left Bayer holding substantial litigation exposure around glyphosate claims and related lawsuits that could result in material settlements and meaningful reputational wear [3].
- Crop Science margins are under sustained pressure from low-cost generics and global overcapacity, particularly from Asian suppliers, while regulatory constraints on crop protection chemistries continue to tighten [9].
- Pharmaceutical revenues face meaningful pressure from pricing constraints and payer policies, alongside regulatory risk and intensifying competition from established pharma and biotech players across key therapeutic areas.
- The company's exposure to operations, commodities, and energy—combined with volatile raw-material costs and the complexity of managing multiple business lines—creates meaningful execution risk and can magnify swings in profitability. [3][3]
Competitive landscape
Bayer operates across Crop Science, Pharmaceuticals and Consumer Health, competing against large chemicals and pharma groups globally. Key rivals include integrated firms like BASF, Novartis, Roche, Pfizer and Corteva—companies that overlap with Bayer across agrochemicals, pharmaceuticals and consumer health. The company's risk profile centers on legacy litigation and regulatory scrutiny stemming from its Monsanto acquisition, R&D and patent exposure in pharmaceuticals, commodity and pricing sensitivity in Crop Science, and macro/currency volatility that can pressure earnings.
| Company | Ticker |
|---|---|
| BASF SE | BAS.XETRA |
| Novartis AG | NOVN.SW |
| Roche Holding AG | ROG.SW |
| Pfizer Inc. | PFE.NYSE |
| Corteva, Inc. | CTVA.NYSE |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Bayer AG NA
Relative Performance vs Benchmarks
| Period | Bayer AG NA | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +4.10% | -0.16% | -1.35% |
| 3M | -9.00% | -8.04% | -18.70% |
| 6M | +25.40% | +20.34% | +14.96% |
| 1Y | +54.96% | +50.78% | +25.81% |
| 3Y | -29.04% | -86.02% | -114.71% |
| 5Y | -20.41% | -81.77% | -111.71% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | -17.4 | 0.8 | 1.3 | 8.3 |
| 1Y ago | -7.5 | 0.5 | 0.8 | 2.9 |
| 3Y ago | 17.5 | 1.1 | 1.3 | 12.5 |
| 5Y ago | -5.2 | 1.3 | 1.5 | 21.7 |
Frequently Asked Questions
Where is the Bayer AG NA stock traded?
What does Bayer AG NA do?
What are the key metrics for BAYN.XETRA?
How has Bayer AG NA's stock price performed?
How is BAYN.XETRA valued?
Does BAYN.XETRA pay dividends?
What are the key risks when investing in BAYN.XETRA?
- The Monsanto acquisition left Bayer holding substantial litigation exposure around glyphosate claims and related lawsuits that could result in material settlements and meaningful reputational wear [web:3].
- Crop Science margins are under sustained pressure from low-cost generics and global overcapacity, particularly from Asian suppliers, while regulatory constraints on crop protection chemistries continue to tighten [web:9].
- Pharmaceutical revenues face meaningful pressure from pricing constraints and payer policies, alongside regulatory risk and intensifying competition from established pharma and biotech players across key therapeutic areas.
- The company's exposure to operations, commodities, and energy—combined with volatile raw-material costs and the complexity of managing multiple business lines—creates meaningful execution risk and can magnify swings in profitability. [page:3][web:3]
Who are the main competitors of Bayer AG NA?
- BASF SE (BAS.XETRA)
- Novartis AG (NOVN.SW)
- Roche Holding AG (ROG.SW)
- Pfizer Inc. (PFE.NYSE)
- Corteva, Inc. (CTVA.NYSE)
When does Bayer AG NA report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 0.11 EUR | 0.29% | 2.31% |
| 2025 | 0.11 EUR | 0.48% | |
| 2024 | 0.11 EUR | 0.40% | |
| 2023 | 2.40 EUR | 4.02% | |
| 2022 | 2.00 EUR | 3.18% | |
| 2021 | 2.00 EUR | 3.68% | |
| 2020 | 2.80 EUR | 4.44% | |
| 2019 | 2.80 EUR | 4.55% | |
| 2018 | 2.76 EUR | 2.73% | |
| 2017 | 2.66 EUR | 2.38% | |
| 2017 | 0.03 EUR | 0.03% | |
| 2016 | 2.46 EUR | 2.48% | |
| 2015 | 2.21 EUR | 1.64% | |
| 2014 | 2.07 EUR | 2.07% | |
| 2013 | 1.87 EUR | 2.34% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 45.58B | 46.61B | 47.64B | 50.74B | 44.08B |
| Operating income (EBIT) | 6.95B | 4.48B | 8.41B | 8.24B | 7.93B |
| Net income | -3.62B | -2.55B | -2.94B | 4.15B | 1.00B |
| Free cash flow | 2.08B | 4.59B | 2.37B | 4.14B | 2.48B |
| Total assets | 110.61B | 110.85B | 116.26B | 124.88B | 120.24B |
| Equity | 25.95B | 31.91B | 32.93B | 38.77B | 33.02B |
| Net debt | 30.77B | 34.62B | 38.88B | 36.48B | 34.97B |
PWP Leeway UG (haftungsbeschränkt)
